Hepatitis C virus (HCV) is an increasing cause of morbidity and mortality in the United States.
Many of the 2.7–3.9 million persons living with HCV infection are unaware they are …

Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus
2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike …

Vaccine efforts to combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
which is responsible for the current coronavirus disease 2019 (COVID-19) pandemic, are …

Many biological functions, including control of the homeostasis and maternofetal transfer of
serum γ-globulins, are mediated by the MHC class I-related neonatal FcR (FcRn). A …

Respiratory syncytial virus (RSV) is the leading cause of viral bronchiolitis and pneumonia
in infants and children. Currently, palivizumab is the only approved monoclonal antibody (mAb…

The study objective was to evaluate the pharmacokinetics (PK), antidrug antibody (ADA),
and safety of motavizumab-YTE (motavizumab with amino acid substitutions M252Y/S254T/…

The COVID-19 pandemic continues to spread throughout the world with an urgent need for
a safe and protective vaccine to effectuate herd protection and control the spread of SARS-…

Background: In the United States, hepatitis C virus (HCV) infection is most prevalent among
adults born from 1945 through 1965, and approximately 50% to 75% of infected adults are …

There is an urgent need for a safe and protective vaccine to control the global spread of
SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy …

Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health
priority. However, no vaccine is currently available to protect this vulnerable population. …